Patents by Inventor Tetsuya Nakatsura

Tetsuya Nakatsura has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10781249
    Abstract: An object of the present invention is to provide: an anti-GPC3 antibody that recognizes an epitope different from that for existing antibodies (e.g., GC33 and GC199) and can specifically bind, even in the form of single chain antibody, to GPC3 localized on a cell membrane; CAR comprising the anti-GPC3 single chain antibody; an immunocompetent cell expressing the CAR; a gene of the anti-GPC3 antibody or a gene of the CAR; a vector comprising the anti-GPC3 antibody gene or the CAR gene; a host cell in which the vector has been introduced; a method for specifically detecting GPC3; and a kit for specifically detecting GPC3. An antibody comprising particular heavy chain CDR1 to CDR3 and particular light chain CDR1 to CDR3 defined in claim 1, and specifically binding to a human-derived GPC3 polypeptide specifically binds to GPC3 localized on a cell membrane. CAR-immunocompetent cells prepared on the basis of CAR comprising such single chain antibody are useful for cancer immunotherapy.
    Type: Grant
    Filed: August 21, 2019
    Date of Patent: September 22, 2020
    Assignees: Yamaguchi University, National Cancer Center, Noile-Immune Biotech, Inc.
    Inventors: Koji Tamada, Yukimi Sakoda, Tetsuya Nakatsura, Keigo Saito
  • Patent number: 10730935
    Abstract: An object of the present invention is to provide: an anti-GPC3 antibody that recognizes an epitope different from that for existing antibodies (e.g., GC33 and GC199) and can specifically bind, even in the form of single chain antibody, to GPC3 localized on a cell membrane; CAR comprising the anti-GPC3 single chain antibody; an immunocompetent cell expressing the CAR; a gene of the anti-GPC3 antibody or a gene of the CAR; a vector comprising the anti-GPC3 antibody gene or the CAR gene; a host cell in which the vector has been introduced; a method for specifically detecting GPC3; and a kit for specifically detecting GPC3. An antibody comprising particular heavy chain CDR1 to CDR3 and particular light chain CDR1 to CDR3 defined in claim 1, and specifically binding to a human-derived GPC3 polypeptide specifically binds to GPC3 localized on a cell membrane. CAR-immunocompetent cells prepared on the basis of CAR comprising such single chain antibody are useful for cancer immunotherapy.
    Type: Grant
    Filed: August 21, 2019
    Date of Patent: August 4, 2020
    Assignees: Yamaguchi University, National Cancer Center, Noile-Immune Biotech, Inc.
    Inventors: Koji Tamada, Yukimi Sakoda, Tetsuya Nakatsura, Keigo Saito
  • Publication number: 20200010804
    Abstract: Provided is a T cell receptor containing, as ? chain complementarity determining regions, respective amino acid sequences of CDR1 to CDR3 respectively shown in SEQ ID NOs: 1 to 3, or respective amino acid sequences of CDR1 to CDR3 respectively shown in SEQ ID NOs: 4 to 6, as ? chain complementarity determining regions, respective amino acid sequences of CDR1 to CDR3 respectively shown in SEQ ID NOs: 7 to 9, or respective amino acid sequences of CDR1 to CDR3 respectively shown in SEQ ID NOs: 10 to 12, and capable of binding to a peptide having the amino acid sequence shown in SEQ ID NO: 27 or a complex of the peptide and HLA-A24.
    Type: Application
    Filed: February 5, 2018
    Publication date: January 9, 2020
    Inventors: Tetsuya Nakatsura, Toshiaki Yoshikawa, Yasushi Uemura, Kyoko Fukuda, Shin Kaneko, Atsutaka Minagawa, Yoshiaki Kassai, Atsushi Matsuda
  • Publication number: 20190367634
    Abstract: An object of the present invention is to provide: an anti-GPC3 antibody that recognizes an epitope different from that for existing antibodies (e.g., GC33 and GC199) and can specifically bind, even in the form of single chain antibody, to GPC3 localized on a cell membrane; CAR comprising the anti-GPC3 single chain antibody; an immunocompetent cell expressing the CAR; a gene of the anti-GPC3 antibody or a gene of the CAR; a vector comprising the anti-GPC3 antibody gene or the CAR gene; a host cell in which the vector has been introduced; a method for specifically detecting GPC3; and a kit for specifically detecting GPC3. An antibody comprising particular heavy chain CDR1 to CDR3 and particular light chain CDR1 to CDR3 defined in claim 1, and specifically binding to a human-derived GPC3 polypeptide specifically binds to GPC3 localized on a cell membrane. CAR-immunocompetent cells prepared on the basis of CAR comprising such single chain antibody are useful for cancer immunotherapy.
    Type: Application
    Filed: August 21, 2019
    Publication date: December 5, 2019
    Applicants: YAMAGUCHI UNIVERSITY, NATIONAL CANCER CENTER, NOILE-IMMUNE BIOTECH, INC.
    Inventors: KOJI TAMADA, YUKIMI SAKODA, TETSUYA NAKATSURA, KEIGO SAITO
  • Publication number: 20190359698
    Abstract: An object of the present invention is to provide: an anti-GPC3 antibody that recognizes an epitope different from that for existing antibodies (e.g., GC33 and GC199) and can specifically bind, even in the form of single chain antibody, to GPC3 localized on a cell membrane; CAR comprising the anti-GPC3 single chain antibody; an immunocompetent cell expressing the CAR; a gene of the anti-GPC3 antibody or a gene of the CAR; a vector comprising the anti-GPC3 antibody gene or the CAR gene; a host cell in which the vector has been introduced; a method for specifically detecting GPC3; and a kit for specifically detecting GPC3. An antibody comprising particular heavy chain CDR1 to CDR3 and particular light chain CDR1 to CDR3 defined in claim 1, and specifically binding to a human-derived GPC3 polypeptide specifically binds to GPC3 localized on a cell membrane. CAR-immunocompetent cells prepared on the basis of CAR comprising such single chain antibody are useful for cancer immunotherapy.
    Type: Application
    Filed: January 10, 2018
    Publication date: November 28, 2019
    Applicants: Yamaguchi University, National Cancer Center, Noile-Immune Biotech, Inc.
    Inventors: Koji TAMADA, Yukimi SAKODA, Tetsuya NAKATSURA, Keigo SAITO
  • Publication number: 20190350979
    Abstract: An undifferentiated stem cell removal agent is provided, containing at least one component selected from the group consisting of the following (a) to (d): (a) a cell that is capable of specifically inhibiting proliferation of a glypican-3-expressing cell; (b) a compound that is capable of specifically inhibiting proliferation of a glypican-3-expressing cell; (c) a cell that is capable of inducing a specific immune response against a glypican-3-expressing cell; and (d) a compound that is capable of inducing a specific immune response against a glypican-3-expressing cell.
    Type: Application
    Filed: December 14, 2017
    Publication date: November 21, 2019
    Inventors: Keiichi FUKUDA, Tetsuya NAKATSURA
  • Publication number: 20190066846
    Abstract: The present invention relates to a method for assisting recurrence risk prediction for hepatocellular carcinoma patients. The method comprises measuring glypican 3 (GPC3) peptide recognized by both a first monoclonal antibody and a second monoclonal antibody in a blood sample of a hepatocellular carcinoma patient, by contacting the sample with the first monoclonal antibody that recognizes a peptide having an amino acid sequence in the N-terminal side of GPC3 and the second monoclonal antibody that recognizes a peptide having an amino acid sequence in the C-terminal side of GPC3, and detecting the complex comprising GPC3 peptide, the first antibody and the second antibody.
    Type: Application
    Filed: September 7, 2018
    Publication date: February 28, 2019
    Applicants: SYSMEX CORPORATION, NATIONAL CANCER CENTER
    Inventors: Tetsuya NAKATSURA, Keigo SAITO, Masahiro MIURA, Kozo SUTO, Takuya IINO
  • Publication number: 20170049870
    Abstract: The present application relates to an antigen peptide derived from the sequence of epidermal growth factor receptor having T790M point mutation and a pharmaceutical composition for the treatment of cancer comprising the peptide.
    Type: Application
    Filed: October 21, 2016
    Publication date: February 23, 2017
    Applicant: Kanagawa Prefectural Hospital Organization
    Inventors: Tetsuro Sasada, Tetsuya Nakatsura, Kazuya Ofuji
  • Patent number: 9505824
    Abstract: The present application relates to an antigen peptide derived from the sequence of epidermal growth factor receptor having T790M point mutation and a pharmaceutical composition for the treatment of cancer comprising the peptide.
    Type: Grant
    Filed: August 8, 2013
    Date of Patent: November 29, 2016
    Assignee: Kanagawa Prefectural Hospital Organization
    Inventors: Tetsuro Sasada, Tetsuya Nakatsura, Kazuya Ofuji
  • Patent number: 9465030
    Abstract: Provided is a kit for diagnosing at a high reproducibility, said kit being produced by preparing a monoclonal antibody against GPC3 and a monoclonal antibody against SPARC that are superior in quality stability to commercially available and commonly employed antibodies, and using these antibodies.
    Type: Grant
    Filed: June 17, 2013
    Date of Patent: October 11, 2016
    Assignees: NATIONAL CANCER CENTER, LSIP, LLC
    Inventors: Tetsuya Nakatsura, Keigo Saito
  • Patent number: 9404925
    Abstract: An object of the present invention to provide: a human pancreatic cancer antigen and/or a human colon cancer antigen that can be applied to the diagnosis and/or treatment of various types of cancers or tumors including pancreatic cancer and colon cancer as representative examples; a gene encoding the same; an anti-cancer vaccine using the same; or the like. The present invention provides a cancer antigen comprising a protein having the amino acid sequence shown in SEQ ID NO: 1; a peptide comprising a portion of said protein and having immune-stimulating activity; an anti-cancer vaccine comprising said peptide; a DNA having the nucleotide sequence shown in SEQ ID NO: 2, or its complementary sequence or a part or full length of these sequence; an anti-cancer vaccine comprising said DNA; and use thereof.
    Type: Grant
    Filed: June 11, 2008
    Date of Patent: August 2, 2016
    Assignee: MEDINET CO., LTD.
    Inventors: Tetsuya Nakatsura, Yasuharu Nishimura
  • Publication number: 20150218248
    Abstract: The present application relates to an antigen peptide derived from the sequence of epidermal growth factor receptor having T790M point mutation and a pharmaceutical composition for the treatment of cancer comprising the peptide.
    Type: Application
    Filed: August 8, 2013
    Publication date: August 6, 2015
    Applicant: Kanagawa Prefectural Hospital Organization
    Inventors: Tetsuro Sasada, Tetsuya Nakatsura, Kazuya Ofuji
  • Publication number: 20150198598
    Abstract: Provided is a kit for diagnosing at a high reproducibility, said kit being produced by preparing a monoclonal antibody against GPC3 and a monoclonal antibody against SPARC that are superior in quality stability to commercially available and commonly employed antibodies, and using these antibodies.
    Type: Application
    Filed: June 17, 2013
    Publication date: July 16, 2015
    Applicants: LSIP, LLC, NATIONAL CANCER CENTER
    Inventors: Tetsuya Nakatsura, Keigo Saito
  • Patent number: 8535942
    Abstract: It is an object of the present invention to identify a glypican-3-derived peptide which can bind to HLA-A2 and activate human killer T cells, so as to provide a means for carrying out an immunotherapy which is able to target approximately 40% of Japanese patients suffering from several types of cancers, which express GPC3 at a high level. The present invention provides a peptide of any of the following (A) or (B): (A) a peptide, which has the amino acid sequence as shown in any one of SEQ ID NOS: 1 to 3; or (B) a peptide, which has an amino acid sequence comprising a substitution or addition of one or two amino acids with respect to the amino acid sequence as shown in any one of SEQ ID NOS: 1 to 3, and which has ability to induce killer T cells.
    Type: Grant
    Filed: September 23, 2011
    Date of Patent: September 17, 2013
    Assignee: Oncotherapy Science, Inc.
    Inventors: Yasuharu Nishimura, Tetsuya Nakatsura, Hiroyuki Komori
  • Publication number: 20130045500
    Abstract: The present invention provides a method of figuring out an effect of a medicine exerting on the same cell quantitatively over a time. A cell evaluation method includes a step of culturing cells on a cell-culture base material that is capable of culturing spheroids, and a step of measuring a change over a time in the number of the spheroids formed through the former step or a percentage of the spheroids formed through the former step relative to an entire cultured cell.
    Type: Application
    Filed: August 18, 2011
    Publication date: February 21, 2013
    Applicants: NATIONAL CANCER CENTER, SCIVAX CORPORATION
    Inventors: Satoru Tanaka, Ruriko Sakamoto, Tetsuya Nakatsura, Manami Shimomura
  • Publication number: 20120040452
    Abstract: It is an object of the present invention to identify a glypican-3-derived peptide which can bind to HLA-A2 and activate human killer T cells, so as to provide a means for carrying out an immunotherapy which is able to target approximately 40% of Japanese patients suffering from several types of cancers, which express GPC3 at a high level. The present invention provides a peptide of any of the following (A) or (B): (A) a peptide, which has the amino acid sequence as shown in any one of SEQ ID NOS: 1 to 3; or (B) a peptide, which has an amino acid sequence comprising a substitution or addition of one or two amino acids with respect to the amino acid sequence as shown in any one of SEQ ID NOS: 1 to 3, and which has ability to induce killer T cells.
    Type: Application
    Filed: September 23, 2011
    Publication date: February 16, 2012
    Applicant: ONCOTHERAPY SCIENCE, INC.
    Inventors: Yasuharu NISHIMURA, Tetsuya NAKATSURA, Hiroyuki KOMORI
  • Patent number: 8053556
    Abstract: It is an object of the present invention to identify a glypican-3-derived peptide which can bind to HLA-A2 and activate human killer T cells, so as to provide a means for carrying out an immunotherapy which is able to target approximately 40% of Japanese patients suffering from several types of cancers, which express GPC3 at a high level. The present invention provides a peptide of any of the following (A) or (B): (A) a peptide, which has the amino acid sequence as shown in any one of SEQ ID NOS: 1 to 3; or (B) a peptide, which has an amino acid sequence comprising a substitution or addition of one or two amino acids with respect to the amino acid sequence as shown in any one of SEQ ID NOS: 1 to 3, and which has ability to induce killer T cells.
    Type: Grant
    Filed: August 8, 2006
    Date of Patent: November 8, 2011
    Assignee: Oncotherapy Science, Inc.
    Inventors: Yasuharu Nishimura, Tetsuya Nakatsura, Hiroyuki Komori
  • Patent number: 8017345
    Abstract: The object of the present invention is to find out another tumor marker which is useful for early diagnosis of melanoma, and provide a diagnostic kit and diagnostic method for malignant melanoma using such marker. The present invention provides a diagnostic kit for malignant melanoma, which comprises an antibody against SPARC and an antibody against GPC3.
    Type: Grant
    Filed: August 9, 2005
    Date of Patent: September 13, 2011
    Assignee: Kumamoto University
    Inventors: Yasuharu Nishimura, Tetsuya Nakatsura, Yoshiaki Ikuta
  • Patent number: 7803533
    Abstract: An object of the present invention is to provide a novel and clinically useful diagnostic agent for malignant melanoma. The present invention provides a diagnostic agent for malignant melanoma, which comprises an antibody against GPC3, or a probe or a primer capable of detecting GPC3 expression.
    Type: Grant
    Filed: October 28, 2004
    Date of Patent: September 28, 2010
    Assignee: Kumamoto Technology & Industry Foundation
    Inventors: Yasuharu Nishimura, Tetsuya Nakatsura
  • Publication number: 20090239806
    Abstract: It is an object of the present invention to identify a glypican-3-derived peptide which can bind to HLA-A2 and activate human killer T cells, so as to provide a means for carrying out an immunotherapy which is able to target approximately 40% of Japanese patients suffering from several types of cancers, which express GPC3 at a high level. The present invention provides a peptide of any of the following (A) or (B): (A) a peptide, which has the amino acid sequence as shown in any one of SEQ ID NOS: 1 to 3; or (B) a peptide, which has an amino acid sequence comprising a substitution or addition of one or two amino acids with respect to the amino acid sequence as shown in any one of SEQ ID NOS: 1 to 3, and which has ability to induce killer T cells.
    Type: Application
    Filed: August 8, 2006
    Publication date: September 24, 2009
    Applicant: KUMAMOTO UNIVERSITY
    Inventors: Yasuharu Nishimura, Tetsuya Nakatsura, Hiroyuki Komori